Coloplast A/S·Healthcare

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Volatility and Risk Coloplast A/S has a beta

Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs, supports stable, mid-to-high single-digit growth expectations for the long term. Management targets 7–8% organic revenue growth and at least 20% ROIC by FY 2029/30, with current dividend yield above 5% but payout ratio unsustainably high.

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026.

Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Healthcare
Medical - Instruments & Supplies
16,741
2014-01-13
0.58